Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliana F Vilacha

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Discovery|January 22, 2020
New directions in antimalarial target validationFernando A Batista, Benjamin Gyau, Juliana F Vilacha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLCLéon C van Kempen, Hangjun Wang, Maria Leonor Aguirre, et al.
Frontiers in Genetics|April 11, 2022
Feasibility of Follow-Up Studies and Reclassification in Spinocerebellar Ataxia Gene Variants of Unknown SignificanceFatemeh Ghorbani, Mohamed Z Alimohamed, Juliana F Vilacha, et al.
JCO Precision Oncology|January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesBart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Clinical Lung Cancer|July 30, 2021
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the LiteratureBart Koopman, Harry J M Groen, Ed Schuuring, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Discovery|January 22, 2020
New directions in antimalarial target validationFernando A Batista, Benjamin Gyau, Juliana F Vilacha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLCLéon C van Kempen, Hangjun Wang, Maria Leonor Aguirre, et al.
Frontiers in Genetics|April 11, 2022
Feasibility of Follow-Up Studies and Reclassification in Spinocerebellar Ataxia Gene Variants of Unknown SignificanceFatemeh Ghorbani, Mohamed Z Alimohamed, Juliana F Vilacha, et al.
JCO Precision Oncology|January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesBart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Clinical Lung Cancer|July 30, 2021
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the LiteratureBart Koopman, Harry J M Groen, Ed Schuuring, et al.
Pageof 1